Nec-1s

Nec-1s (necrostatin-1s) is a potent, highly selective, and blood-brain barrier-permeable small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). Developed by researchers at Harvard University and the Shanghai Institute of Organic Chemistry, Nec-1s is a stable derivative of the first-generation RIPK1 inhibitor necrostatin-1 (Nec-1). Unlike Nec-1, Nec-1s does not exhibit off-target inhibition of indoleamine 2,3-dioxygenase (IDO), making it a much more specific tool for studying RIPK1-mediated necroptosis and neuroinflammation. Nec-1s is widely utilized as a preclinical research reagent to investigate the therapeutic potential of necroptosis inhibition in various pathological conditions, including neurodegenerative diseases (such as Alzheimer's disease and amyotrophic lateral sclerosis), ischemia-reperfusion injury, acute kidney injury, and systemic inflammatory disorders.

Other names

5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione5-((7-chloro-1H-indol-3-yl)methyl)-3-methylimidazolidine-2,4-dionenecrostatin 1Snecrostatin1Snecrostatin-1Snecrostatin 2necrostatin2necrostatin-2necrostatin 2 racematenecrostatin2 racematenecrostatin-2 racemate